New drug RX001 for advanced lung cancer with KRAS mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called RX001 for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change (KRAS mutation) and has stopped responding to standard treatments. The goal is to see if RX001 is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have advanced non-small cell lung cancer with a KRAS mutation that has worsened after standard treatments (or you cannot receive them)
- You have at least one tumor that can be seen on a CT scan and is injectable for the study drug
- You are able to take care of most daily activities yourself (ECOG 0 or 1) and expected to live at least 12 more weeks
- Your blood and organ functions are within a healthy range
- You have not had certain heart conditions (like a heart attack in the past year), bleeding disorders, or active infections (like hepatitis B/C or HIV)
- You have not received other cancer treatments in the last 28 days (or recovered from side effects), and no radiation to large areas in the last 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.